Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Market Cap	41.20B -15.3%
Revenue (ttm)	3.10B +31.7%
Net Income	-751.18M
EPS	-0.74
Shares Out	1.03B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,366,600
Open	20.00
Previous Close	18.86
Day's Range	19.42 - 20.82
52-Week Range	15.25 - 38.64
Beta	0.58
Analysts	Buy
Price Target	29.23 (+49.36%)
Earnings Date	Aug 26, 2026

About HKG:1877

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,903
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1877

Financial Performance

In 2025, HKG:1877's revenue was 2.50 billion, an increase of 28.23% compared to the previous year's 1.95 billion. Losses were -875.17 million, -31.68% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 4 analysts, the average rating for 1877 stock is "Buy." The 12-month stock price target is $29.23, which is an increase of 49.36% from the latest price.

Price Target

$29.23

(49.36% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error